logo
Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B
High proportion of unrelated HIV-1 intersubtype recombinants in the Mbeya region of southwest Tanzania
Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs
Lymphoid tissue viral burden and duration of viral suppression in plasma
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy
Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients
Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/l
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children
A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding
Epidemiological analysis of the quality of HIV sero-surveillance in the world: how well do we track the epidemic?
Timing of the HIV-1 subtype C epidemic in Ethiopia based on early virus strains and subsequent virus diversification
`Chemical condoms’ for the prevention of HIV infection: evaluation of novel agents against SHIV89.6PD in vitro and in vivo
HIV-1 seroconversion in United States Army active duty personnel, 1985–1999
Absence of a recognizable seroconversion illness in Africans infected with HIV-1
Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy
Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials
End-of-life care
Leber's hereditary optic neuropathy in the setting of nucleoside analogue toxicity
Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis
Discontinuation of primary Pneumocystis carinii prophylaxis after reconstitution of CD4 cell counts in HIV-infected children
Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up